{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T21:40:37Z","timestamp":1770500437085,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.idnow.2020.11.015","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T23:53:30Z","timestamp":1611014010000},"page":"304-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prolonged cefazolin course for treatment of methicillin susceptible staphylococcus species infections and the impact on the emergence of multidrug-resistant bacteria during cloxacillin shortage"],"prefix":"10.1016","volume":"51","author":[{"given":"Marc-Olivier","family":"Vareil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amaury","family":"Barret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Vinclair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brice","family":"Guerpillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Leyssene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Christine","family":"Jaouen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8568-6982","authenticated-orcid":false,"given":"Laure","family":"Alleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Wille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.idnow.2020.11.015_bib0120","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/AAC.00317-09","article-title":"Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure","volume":"53","author":"Nannini","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idnow.2020.11.015_bib0125","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1128\/AAC.00052-12","article-title":"Prevalence of blaZ gene types and the inoculum effect with cefazolin among bloodstream isolates of methicillin-susceptible Staphylococcus aureus","volume":"56","author":"Livorsi","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idnow.2020.11.015_bib0135","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cmi.2017.07.003","article-title":"Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a narrative review","volume":"24","author":"Loubet","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"10.1016\/j.idnow.2020.11.015_bib0140","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/cid\/cix287","article-title":"Comparative Effectiveness of Cefazolin versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study","volume":"65","author":"McDanel","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.idnow.2020.11.015_bib0145","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1093\/jac\/dky259","article-title":"Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins","volume":"73","author":"Bidell","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idnow.2020.11.015_bib0150","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s12879-018-3418-9","article-title":"Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis","volume":"18","author":"Shi","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.idnow.2020.11.015_bib0155","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01816-17","article-title":"Systematic Review and Meta-analysis of the Safety of Antistaphylococcal Penicillins Compared to Cefazolin","volume":"62","author":"Eljaaly","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idnow.2020.11.015_bib0160","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1128\/AAC.00243-16","article-title":"Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center","volume":"60","author":"Pollett","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2020.11.015_bib0165","unstructured":"C\u00e9fazoline et troubles de la coagulation\u00a0: mesures de pr\u00e9caution | GPIP [Internet]. http:\/\/gpip.sfpediatrie.com\/actualite\/c%C3%A9fazoline-et-troubles-de-la-coagulation-mesures-de-pr%C3%A9caution [cited 2018 Nov 9]. 20 novembre 2017."},{"issue":"3","key":"10.1016\/j.idnow.2020.11.015_bib0170","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijantimicag.2018.04.007","article-title":"Acute kidney injury during treatment with high-dose cloxacillin: a report of 23 cases and literature review","volume":"52","author":"Lavergne","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.idnow.2020.11.015_bib0175","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40121-017-0148-z","article-title":"The Safety and Economic Impact of Cefazolin versus Nafcillin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections","volume":"6","author":"Flynt","year":"2017","journal-title":"Infect Dis Ther"},{"issue":"6","key":"10.1016\/j.idnow.2020.11.015_bib0180","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jama.2020.0103","article-title":"Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal \u03b2-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial","volume":"323","author":"Tong","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.idnow.2020.11.015_bib0185","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13613-017-0255-8","article-title":"Systematic overdosing of oxa- and cloxacillin in severe infections treated in ICU: risk factors and side effects","volume":"7","author":"Neuville","year":"2017","journal-title":"Ann Intensive Care"},{"issue":"3","key":"10.1016\/j.idnow.2020.11.015_bib0190","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/jac\/15.3.319","article-title":"The influence of single dose intravenous antibiotics on faecal flora and emergence of Clostridium difficile","volume":"15","author":"Ambrose","year":"1985","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.idnow.2020.11.015_bib0195","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1007\/BF01644233","article-title":"Impact of injectable cephalosporins on the gastrointestinal microflora: observations in healthy volunteers and hospitalized patients","volume":"13","author":"Knothe","year":"1985","journal-title":"Infection"},{"issue":"7","key":"10.1016\/j.idnow.2020.11.015_bib0200","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s005950200105","article-title":"Changes in the intestinal flora after the administration of prophylactic antibiotics to patients undergoing a gastrectomy","volume":"32","author":"Takesue","year":"2002","journal-title":"Surg Today"},{"issue":"2","key":"10.1016\/j.idnow.2020.11.015_bib0205","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00134-012-2769-8","article-title":"Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012","volume":"39","author":"Dellinger","year":"2013","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.idnow.2020.11.015_bib0210","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP [Internet]. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50 [cited 2020 Aug 13]."},{"issue":"3","key":"10.1016\/j.idnow.2020.11.015_bib0215","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/cid\/ciu301","article-title":"Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting","volume":"59","author":"Youngster","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idnow.2020.11.015_bib0220","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmi.2017.07.001","article-title":"Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea","volume":"24","author":"Lee","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"8.","key":"10.1016\/j.idnow.2020.11.015_bib0225","article-title":"Prevalence of a Cefazolin Inoculum Effect Associated with blaZ Gene Types among Methicillin-Susceptible Staphylococcus aureus Isolates from Four Major Medical Centers in Chicago","volume":"62","author":"Wang","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idnow.2020.11.015_bib0230","doi-asserted-by":"crossref","first-page":"e023151","DOI":"10.1136\/bmjopen-2018-023151","article-title":"Efficacy of cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial","volume":"8","author":"Burdet","year":"2018","journal-title":"BMJ Open"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991920000317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991920000317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:29:41Z","timestamp":1763018981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666991920000317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S2666991920000317"],"URL":"https:\/\/doi.org\/10.1016\/j.idnow.2020.11.015","relation":{},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolonged cefazolin course for treatment of methicillin susceptible staphylococcus species infections and the impact on the emergence of multidrug-resistant bacteria during cloxacillin shortage","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idnow.2020.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}